FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
ESPERITE tops the trisomies detection market with TRANQUILITY: the CE-IVD marked and risk-free fetal DNA test that accurately detects Down syndrome (>99,9%), trisomies 18 and 13, sexual aneuploidies, microdeletions, and the sex of the baby, reporting results within 5 days. TRANQUILITY's entire testing process for trisomies (sample collection, preparation, sequencing, bioinformatics analysis and report) is compliant with the European In Vitro Diagnostics Medical Devices Directive 98/79/EC and has been certified by an independent body -UL International. TRANQUILITY combines the technologies of Iona and InKaryo, the recently acquired company now part of the ESPERITE group. read more
GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of innovative immunotherapies targeting cancers caused by the human papillomavirus (HPV), today announces its net cash position and equivalents and its highlights from the first quarter of 2015. read more
Toonaangevend ontwikkelaar en leverancier van industriële test- en meetoplossingen Test & Measurement Solutions (T&M Solutions) noteerde in 2014 een groei van 15%, ondanks de crisis. Om haar internationale expansie verder te zetten en extra arbeidsplaatsen te creëren, investeert het Limburgse bedrijf in nieuwe vestigingen in Nederland en Polen. Daarnaast zet het bedrijf volop in op blijvende bijscholing van haar medewerkers om hoogtechnologische expertise te garanderen bij het verstrekken van kwaliteitsgaranties voor producten en bij het optimaliseren van productieprocessen. read more
BONE THERAPEUTICS, a leader in bone cell therapy addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the publication of its annual report including the consolidated full year results for 2014, prepared in accordance with IFRS as adopted by the European Union. read more
Galapagos NV (Euronext: GLPG) announced today that the selective JAK1 inhibitor filgotinib as once-daily monotherapy showed rapid improvements in signs and symptoms of moderately severe, active rheumatoid arthritis (RA) and met key efficacy endpoints after 12 weeks of treatment in the DARWIN 2 Phase 2B study. The study achieved its primary endpoint at all doses and demonstrated statistically significant improvements in ACR20 response versus placebo after 12 weeks of treatment. In addition, statistically significant ACR50 response and DAS28(CRP) decrease were achieved with all dose levels. Filgotinib was well tolerated in this study. Hemoglobin levels increased. These first 12 week results in the ongoing 24 week study are consistent with the efficacy and safety profile of filgotinib observed in prior clinical studies. read more
BONE THERAPEUTICS, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the official opening of its new headquarters at the Gosselies Biopark in Belgium. Bone Therapeutics’ new facility is being officially opened in the presence of Mr Paul Magnette, Minister-President of Wallonia, and Mr Jean-Claude Marcourt, Vice-President of the Walloon Government. read more
Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative immunotherapies targeting cancers caused by the human papillomavirus (HPV), announces today it will participate in the SmallCap Event taking place in Paris at the Hotel Paris Pullman Eiffel Tower on April 27th & 28th, 2015. read more
MDxHealth SA (Euronext: MDXH.BR) announced today that it has been named as one of the winners of the Corporate LiveWire Innovation & Excellence Awards. The awards are in recognition of innovation and excellence that recipient companies, teams and individuals have shown amid ongoing global economic uncertainty. read more
"Publicly-listed Belgian biotech is experiencing very strong momentum, driven by pipeline developments and market enthusiasm for high-growth companies." Jan De Kerpel, KBC Securities read more
arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, and de Duve Institute / Université Catholique de Louvain (UCL) / WELBIO (BE) today announced the publication of new data showing that the preclinical therapeutic antibody ARGX-115 blocks the activity of GARP, a novel immune checkpoint. These findings were published in the leading journal Science Translational Medicine and suggest potential for the antibody candidate in cancer immunotherapy. read more